KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Liabilities and Shareholders Equity (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $38.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 2.23% year-over-year to $38.7 million, compared with a TTM value of $154.2 million through Sep 2025, down 6.57%, and an annual FY2024 reading of $38.8 million, down 10.36% over the prior year.
  • Liabilities and Shareholders Equity was $38.7 million for Q3 2025 at TherapeuticsMD, roughly flat from $38.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $239.3 million in Q1 2021 and bottomed at $38.2 million in Q1 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $97.6 million, with a median of $52.1 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity grew 18.24% in 2021, then crashed 63.28% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $169.5 million in 2021, then crashed by 46.62% to $90.5 million in 2022, then crashed by 52.12% to $43.3 million in 2023, then fell by 10.36% to $38.8 million in 2024, then dropped by 0.39% to $38.7 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for TXMD at $38.7 million in Q3 2025, $38.5 million in Q2 2025, and $38.2 million in Q1 2025.